A Long-Term Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Multiple Maintenance Doses of Oral Once Daily Aleniglipron for Chronic Weight Management in Adults With Obesity or Overweight and Type 2 Diabetes Mellitus (ACCOMPLISH-2)
A Long-Term Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Multiple Maintenance Doses of Oral Once Daily Aleniglipron for Chronic Weight Management in Adults With Obesity or Overweight and Type 2 Diabetes Mellitus (ACCOMPLISH-2)
This is randomized, double-blind, placebo-controlled study of the long-term efficacy, safety, and tolerability of multiple doses of aleniglipron in participants living with overweight or obesity and T2DM. Participants will be randomized to aleniglipron or placebo for a total of 76 weeks of treatment.
Inclusion Criteria:
Exclusion Criteria:
GSBRClinicalTrials@structuretx.com1-650-457-1959
Birmingham, Alabama 35242, United States
GSBRClinicalTrials@structuretx.com
GSBRClinicalTrials@structuretx.com
GSBRClinicalTrials@structuretx.com
GSBRClinicalTrials@structuretx.com
GSBRClinicalTrials@structuretx.com
GSBRClinicalTrials@structuretx.com
GSBRClinicalTrials@structuretx.com
GSBRClinicalTrials@structuretx.com
GSBRClinicalTrials@structuretx.com
GSBRClinicalTrials@structuretx.com
GSBRClinicalTrials@structuretx.com
GSBRClinicalTrials@structuretx.com
GSBRClinicalTrials@structuretx.com
GSBRClinicalTrials@structuretx.com
GSBRClinicalTrials@structuretx.com
GSBRClinicalTrials@structuretx.com
GSBRClinicalTrials@structuretx.com
GSBRClinicalTrials@structuretx.com
GSBRClinicalTrials@structuretx.com
GSBRClinicalTrials@structuretx.com
GSBRClinicalTrials@structuretx.com
GSBRClinicalTrials@structuretx.com
GSBRClinicalTrials@structuretx.com
GSBRClinicalTrials@structuretx.com
GSBRClinicalTrials@structuretx.com
GSBRClinicalTrials@structuretx.com
GSBRClinicalTrials@structuretx.com
GSBRClinicalTrials@structuretx.com
GSBRClinicalTrials@structuretx.com
GSBRClinicalTrials@structuretx.com
GSBRClinicalTrials@structuretx.com
GSBRClinicalTrials@structuretx.com
GSBRClinicalTrials@structuretx.com
GSBRClinicalTrials@structuretx.com
GSBRClinicalTrials@structuretx.com
GSBRClinicalTrials@structuretx.com
GSBRClinicalTrials@structuretx.com
GSBRClinicalTrials@structuretx.com
GSBRClinicalTrials@structuretx.com
GSBRClinicalTrials@structuretx.com
GSBRClinicalTrials@structuretx.com
GSBRClinicalTrials@structuretx.com
GSBRClinicalTrials@structuretx.com
GSBRClinicalTrials@structuretx.com
GSBRClinicalTrials@structuretx.com
GSBRClinicalTrials@structuretx.com
GSBRClinicalTrials@structuretx.com
GSBRClinicalTrials@structuretx.com
GSBRClinicalTrials@structuretx.com
GSBRClinicalTrials@structuretx.com
GSBRClinicalTrials@structuretx.com
GSBRClinicalTrials@structuretx.com
GSBRClinicalTrials@structuretx.com
GSBRClinicalTrials@structuretx.com
GSBRClinicalTrials@structuretx.com
GSBRClinicalTrials@structuretx.com
GSBRClinicalTrials@structuretx.com
GSBRClinicalTrials@structuretx.com
GSBRClinicalTrials@structuretx.com
GSBRClinicalTrials@structuretx.com
GSBRClinicalTrials@structuretx.com
GSBRClinicalTrials@structuretx.com
GSBRClinicalTrials@structuretx.com
GSBRClinicalTrials@structuretx.com
GSBRClinicalTrials@structuretx.com
GSBRClinicalTrials@structuretx.com
GSBRClinicalTrials@structuretx.com
GSBRClinicalTrials@structuretx.com
GSBRClinicalTrials@structuretx.com
GSBRClinicalTrials@structuretx.com
GSBRClinicalTrials@structuretx.com
GSBRClinicalTrials@structuretx.com
GSBRClinicalTrials@structuretx.com